medigraphic.com
ISSN 1561-3119 (Electronic)

2021, Number 3

<< Back Next >>

Rev Cubana Pediatr 2021; 93 (3)

Use of CIGB-258 peptide in a pediatric patient with severe pneumonia due to SARS-CoV-2

Rubio OR, Rodríguez MVS, Leiva MM, Domínguez DMC

Language: Spanish
References: 32
Page: 1-14
PDF size: 331.49 Kb.


ABSTRACT

Introduction: The clinical presentation of the disease caused by SARS-CoV-2 is heterogeneous. Patients may be asymptomatic or have mild upper respiratory tract disease, or develop severe pneumonia that can progress to acute respiratory distress syndrome and lead to death. The pathophysiology of severe forms of the disease is characterized by a marked hyperinflammation. Therapies that modulate the immune response can be crucial in treating and preventing this state. The CIGB-258 peptide, brand name Jusvinza, is a therapeutic option for this purpose, due to its immunomodulatory properties.
Objective: Describe the clinical evolution of a pediatric patient with severe pneumonia due to SARS-CoV-2, and treated with the CIGB-258 peptide.
Case Presentation: A 12-year-old adolescent with refractory epilepsy, infantile cerebral palsy, and an epidemiological history of contact with a patient positive to PCR confirmatory test for SARS-CoV-2 who, eight days after contact, shows clinical, radiographic, and laboratory evidence of severe pneumonia due to COVID-19. Within the therapeutic protocol, he received treatment with CIGB-258 immunomodulatory peptide, with a favorable evolution and hospital discharge.
Conclusions: The use of CIGB-258 peptide in the treatment of severe pneumonia due to COVID-19 in pediatrics could contribute to prevent progression to the critical stages of the disease.


REFERENCES

  1. Zhu N, Zhang D, Wang W et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. New Engl J Med. (2020);382(8):727–733. https://doi.org/10.1056/NEJMoa2001017.

  2. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus disease 2019 (COVID-19): A review: A review. JAMA. 2020;324(8):782-93.

  3. Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: An overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J. 2020;39(5):355-68.

  4. Götzinger F, Santiago-García B, Noguera-Julián A, Lanaspa M, Lancella L, Calò Carducci FI, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4(9):653-61.

  5. Espinosa Rosales FJ. Inmunopatología de la infección por virus SARS-CoV-2. Acta pediátr Méx. 2020;41(4S1):42.

  6. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405-7.

  7. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin. Rheumatol. (2020) 39(70) 2085–2094, https://doi.org/10.1007/s10067-020-05190-5

  8. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4.

  9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.

  10. Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee S-S, Chakraborty C. Tocilizumab: A therapeutic option for the treatment of cytokine storm syndrome in COVID-19. Arch Med Res. 2020;51(6):595-7.

  11. Solis Cartas Urbano, Martinez Larrarte Jose Pedro. Opciones terapéuticas al síndrome de liberación de citocinas en pacientes con la COVID-19. Rev Cubana Med Milit. 2020 [citado 2021 Mar 28]; 49( 3 ):e783. Disponible en: http://www.revmedmilitar.sld.cu/index.php/mil/article/view/783

  12. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) . JAMA. (2020) 324(8):782-793. https://doi.org/10.1001/jama.2020.12839

  13. Dominguez MDC, Lorenzo N, Barbera A, Darrasse-Jeze G, Hernández MV, Torres A, et al. An altered peptide ligand corresponding to a novel epitope from heat-shock protein 60 induces regulatory T cells and suppresses pathogenic response in an animal model of adjuvant-induced arthritis. Autoimmunity. 2011;44(6):471-82.

  14. Lorenzo N. (2017) APL-1, an altered peptide ligand derived from heat-shock protein, alone or combined with methotrexate attenuates murine collagen induced arthritis. Clin Exp Med. 2017;17:209–16.

  15. Corrales O. (2019) CIGB-814, an altered peptide ligand derived from human heat-shock protein 60, decreases anti-cyclic citrullinated peptides antibodies in patients with rheumatoid arthritis. Clin Rheumatol. 2019;38:955–60.

  16. Barberá A. (2016). APL1, an altered peptide ligand derived from human heat-shock protein 60, increases the frequency of Tregs and its suppressive capacity against antigen responding effector CD4+T cells from rheumatoid arthritis patients. Cell Stress Chaper. 2016;21:735–44.

  17. Venegas-Rodriguez R. CIGB-258 Immunomodulatory Peptide: Compassionate Use for Critical and Severe COVID-19 Patients. Austin J Pharmacol Ther. 2020;8(1):1119.

  18. Hernandez-Cedeño M. CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients. Cell Stress Chaper. 2021; 26:515–525 .doi: 10.1007/s12192-021-01197-2

  19. Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos. Jusvinza, Emergency Use Authorization for the treatment of patients with COVID-19 (Autorizo de Uso de Emergencia a Jusvinza, para el tratamiento de pacientes con COVID-19).La Habana; CECME, 2020 junio 17. Disponible en: https://www.cecmed.cu/covid-19/aprobaciones/jusvinza-cigb-258-1.

  20. Ministry of Public Health of Cuba. Protocolo de Actuación Nacional para la COVID-19 Versión 1.5 . Havana, 2020 August. Disponible en: https://www.mined.gob.cu/wp-content/uploads/2020/08/VERSION-5-DEL-PROTOCOLO-PARA-PUBLICAR-13-DE-AGOSTO-2020_compressed.pdf.

  21. Tezer H, Bedi̇r Demi̇rdağ T. Novel coronavirus disease (COVID-19) in children. Turk J Med Sci. 2020;50(SI-1):592-603.

  22. Graff K, Smith C, Silveira L, Jung S, Curran-Hays S, Jarjour J, et al. Risk factors for severe COVID-19 in children. Pediatr Infect Dis J. 2021; 40 (137-e145).doi: http://dx.doi.org/10.1097/INF.0000000000003043.

  23. Meena J, Yadav J, Saini L, Yadav A, Kumar J. Clinical features and outcome of SARS-CoV-2 infection in children: A systematic review and meta-analysis. Indian Pediatr. 2020;57(9):820-6.

  24. Zimmermann P, Curtis N. COVID-19 in children, pregnancy and neonates: A review of epidemiologic and clinical features: A review of epidemiologic and clinical features. Pediatr Infect Dis J. 2020;39(6):469-77.

  25. Parra Gordo ML, Weiland GB, García MG, Choperena GA. Aspectos radiológicos de la neumonía COVID-19: evolución y complicaciones torácicas. Radiologia. 2021;63(1):74-88.

  26. García-Salido A, de Carlos Vicente JC, Belda Hofheinz S, Balcells Ramírez J, Slöcker Barrio M; Spanish Pediatric Intensive Care Society working group on SARS-CoV-2 infection, severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. Crit Care. 2020;24(1).doi: http://dx.doi.org/10.1186/s13054-020-03332-4.

  27. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.

  28. Song W, Li J, Zou N, Guan W, Pan J, Xu W. Clinical features of pediatric patients with coronavirus disease (COVID-19). J Clin Virol. 2020;127(104377):104377.

  29. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-8.

  30. Marta-Enguita J, Corroza-Laviñeta J, Ostolaza A. Factores de riesgo y predictores de gravedad en pacientes hospitalizados por COVID-19: análisis de 52 casos. Med Clin (Barc). 2020;155(8):360-1.

  31. Mudatsir M, Fajar JK, Wulandari L, Soegiarto G, Ilmawan M, Purnamasari Y, et al. Predictors of COVID-19 severity: a systematic review and meta-analysis. F1000Res. 2020;9:1107.

  32. Götzinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4(9):653661. doi:10.1016/S2352-4642(20)30177-2.




2020     |     www.medigraphic.com